Trial Profile
A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms A-PREDICT
- 30 Jan 2024 Status changed from active, no longer recruiting to completed.
- 06 Feb 2019 Planned End Date changed from 1 Sep 2016 to 1 Dec 2019.
- 06 Feb 2019 Status changed from recruiting to active, no longer recruiting.